Market Indices
Sector Heatmap
ACAD — Acadia Pharmaceuticals Inc.
NasdaqAcadia Pharmaceuticals Inc.
- O
- 19.95
- H
- 20.19
- L
- 19.59
- V
- 2.73M
ACAD — Latest News & Headlines
20 StoriesAcadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Acadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History Yahoo! Finance Canada
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe Stocktwits
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - Simply Wall Street
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push Simply Wall Street
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets - TradingView
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets TradingView
Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history Yahoo Finance Singapore
$ACAD stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
$ACAD stock is down 8% today. Here's what we see in our data. Quiver Quantitative
A dosing patent could add nearly five years of U.S. protection for a Rett syndrome treatment - stocktitan.net
A dosing patent could add nearly five years of U.S. protection for a Rett syndrome treatment stocktitan.net
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - theglobeandmail.com
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal theglobeandmail.com
Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss - Trefis
Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss Trefis
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI - Schaeffer's Investment Research
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI Schaeffer's Investment Research
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - TradingView
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% TradingView
A second measure favored the higher dose. The Alzheimer’s drug narrowly missed its main test. - stocktitan.net
A second measure favored the higher dose. The Alzheimer’s drug narrowly missed its main test. stocktitan.net
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop Yahoo Finance
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Yahoo Finance
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts Yahoo Finance
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - TIKR.com
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 TIKR.com
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - Yahoo Finance
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint Yahoo Finance
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) Seeking Alpha
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results GuruFocus
Acadia Pharmaceuticals: Remlifanserin Is In Trouble - Seeking Alpha
Acadia Pharmaceuticals: Remlifanserin Is In Trouble Seeking Alpha